Medtronic closes 1st phase of Symplicity renal denervation feasibility trial

October 3, 2012 by MassDevice staff

Medtronic said the 1st phase of a small trial of the next iteration of its Symplicity device for treating high blood pressure showed a 100% success rate.


Medtronic (NYSE:MDT) said it's closed the 1st phase of a feasibility trial for its next-generation Symplicity renal denervation device for high blood pressure.

The 9-patient trial delivered a 100% acute success rate in accessing the renal arteries and delivering the therapy, according to a press release.

"We look forward to moving forward with our clinical evaluation of this next-generation system that aims to augment our portfolio by offering more sophisticated features that should benefit both physicians and patients," Medtronic's president of coronary & renal denervation Sean Salmon said in prepared remarks. "This feasibility study represents Medtronic's commitment to providing physicians with a broader range of solutions for performing renal denervation and to collaborating with physician partners in the ongoing evaluation of this ground-breaking therapy."

Sign up to get our free newsletters delivered straight to your inbox

Earlier this week, the Fridley, Minn.-based medical device company touted the launch of another renal denervation trial, testing the Symplicity system against drug therapy alone in patients in Japan.

In September, Medtronic said an analysis of its Symplicity HTN 2 trial showed that the procedure is a cost-effective way to treat resistant hypertension.